The University of Pamplona , is a public, departmental, coeducational research university based primarily in the city of Pamplona, Norte de Santander, Colombia. The university also has two satellite campuses in the department, in the cities of Cúcuta and Villa del Rosario. Wikipedia.
Ferrer M.,University of Pamplona
Expert Opinion on Drug Metabolism and Toxicology | Year: 2011
Introduction: There have recently been guidelines developed for the diagnosis and treatment of rhinitis and urticaria. For both conditions, second-generation antihistamines remain as the first-line therapy. Areas covered: The article presents the current pharmacology, chemical properties, pharmacokinetics and metabolism of levocetirizine. The article also reviews the clinical efficacy of levocetirizine for seasonal allergic and perennial rhinitis, as well as chronic urticaria. The article is formed through the review of all the published literature in English retrieved from the PubMed/MEDLINE database between 1966 and March 2011 using the search terms: levocetirizine, allergic rhinitis, chronic urticaria and antihistamine. Furthermore, the article also reviews data provided by the manufacturer in addition to reports from governmental agencies. Expert opinion: Levocetirizine has several pharmacokinetic properties that are desirable for an antihistamine providing a combination of both potency and safety. Its clinical advantages are derived from its rapid and extensive absorption, limited distribution and its very low degree of metabolism. Furthermore, levocetirizine scores very highly in terms of clinical efficacy as well as in patient/physician satisfaction studies. Given the lack of large multi-center studies that compare the treatment options for urticaria, clinicians must rely on potency studies when choosing treatment and levocetirizine does score very highly. However, other potent skin antihistamines, such as desloratadine or fexofenadine, should be preferred for patients who have a strict contraindication to the sedative effects of the drug. © 2011 Informa UK, Ltd.
Diaz S.,University of Pamplona
Journal of Lightwave Technology | Year: 2016
In this paper, a new stable dual-wavelength erbium fiber ring laser for remote temperature measurements is proposed and experimentally demonstrated. The sensing element is composed of two fiber Bragg gratings and sensor interrogation is achieved with a dual-wavelength erbium fiber ring laser. This configuration is made by creating two symmetrical laser cavities with similar optical power. This topology allows the performance of two laser emission lines in single-longitudinal mode (SLM) and with power instability lower than 0.23 dB, and an optical signal-to-noise ratio higher than 30 dB for all the emitted wavelengths. The application of this system for remote temperature measurements has been demonstrated even though the SLM regime cannot be maintained. © 1983-2012 IEEE.
Romano A.,Allergy Unit |
Torres M.J.,Carlos Haya Hospital |
Castells M.,Harvard University |
Sanz M.L.,University of Pamplona |
Blanca M.,Carlos Haya Hospital
Journal of Allergy and Clinical Immunology | Year: 2011
The present article addresses the advances in the diagnosis and management of drug hypersensitivity reactions that were discussed in the 4th Drug Hypersensitivity Meeting held in Rome in April 2010. Such reactions can be classified as immediate or nonimmediate according to the time interval between the last drug administration and onset. Immediate reactions occur within 1 hour, and nonimmediate reactions occur after more than 1 hour. Clinical and immunologic studies suggest that type-I (IgE-mediated) and type-IV (T cell-mediated) pathogenic mechanisms are involved in most immediate and nonimmediate reactions, respectively. In diagnosis prick, patch, and intradermal tests are the most readily available tools. Determination of specific IgE levels is still the most common in vitro method for diagnosing immediate reactions. New diagnostic tools, such as the basophil activation test, the lymphocyte activation test, and enzyme-linked immunospot assays for analysis of the frequency of antigen-specific, cytokine-producing cells, have been developed for evaluating either immediate or nonimmediate reactions. The sensitivity of allergologic tests is not 100%; therefore in selected cases provocation tests are necessary. In the diagnosis of nonallergic hypersensitivity reactions to nonsteroidal anti-inflammatory drugs, the provocation test with the suspected drug still represents the "gold standard." However, there was no consensus regarding the use of this test in subjects with histories of hypersensitivity reactions to 1 (single reactors) or more (multiple reactors) nonsteroidal anti-inflammatory drugs. With regard to management, desensitization allows patients to be treated with irreplaceable chemotherapy agents, such as taxanes, platinum salts, and mAbs, to which they have presented hypersensitivity reactions. Desensitization also permits the use of aspirin in aspirin-sensitive patients undergoing revascularization and in subjects with aspirin-exacerbated respiratory disease. © 2011 American Academy of Allergy, Asthma & Immunology.
News Article | November 16, 2016
Cambridge/Boston, Mass. - November 16, 2016 - Harvard University has completed a license agreement with Magenta Therapeutics, a new startup company launched in Cambridge, for a portfolio of technologies with the potential to transform blood stem cell transplants from a "treatment of last resort" into a safer, more efficient therapy for patients with blood diseases and immune disorders. To date, even at the cutting edge of hematopoietic (blood) stem cell transplantation, the severe side effects and mortality risk involved in conditioning--preparing patients for the procedure--have been a major obstacle to expanding access to this life-saving treatment. Recent scientific advances in conditioning and new methods for the harvesting and propagation of donor stem cells could offer a fundamentally new approach. The license agreement spearheaded by Harvard's Office of Technology Development (OTD) grants Magenta access to a platform of stem cell technologies developed at Harvard, Massachusetts General Hospital (MGH), and Boston Children's Hospital. Magenta announced today that it has raised $48.5M in Series A financing led by Third Rock Ventures and Atlas Venture along with GV (formerly Google Ventures), Access Industries, and Partners Innovation Fund. "This suite of technologies could be game-changing for hematopoietic stem cell transplantation," said Vivian Berlin, a Director of Business Development for Harvard OTD. "Placing these technologies 'under one roof' in a venture focused solely on transforming the field of transplantation provides the highest probability that they will result in therapies that improve the lives of patients." The foundational technology was developed in the lab of David Scadden, MD, whose laboratory at Harvard and MGH studies the biology of hematopoietic stem cells--the cells in bone marrow that give rise to red blood cells--with a long-term goal of understanding how the corruption of these cells can give rise to leukemia. "We've been very interested in understanding the basic biology of those processes, always with an idea that by so doing we might be able to find ways to come up with new biologically driven therapies," explained Scadden, who is Gerald and Darlene Jordan Professor of Medicine and Professor of Stem Cell and Regenerative Biology at Harvard and director of the Center for Regenerative Medicine at MGH. "The idea that we could improve regeneration of the blood and the immune system through transplant is something that's been an area of emphasis for a number of years--really, for most of my career." At Harvard, Scadden also chairs the Department of Stem Cell and Regenerative Biology and is cofounder and codirector of the Harvard Stem Cell Institute. "Hematopoietic stem cells have the remarkable ability to develop into all cells in the blood and immune system, and have been used to transplant over one million patients in the past 50 years," said Jason Gardner, Magenta's Chief Executive Officer, President, and Cofounder. "Technical and scientific hurdles have relegated stem cell transplantation to a last resort for deadly diseases today, but new science has emerged that can be advanced to the clinic that could fundamentally open up this powerful medicine to patients suffering from earlier stage cancers, bone marrow failure and a large set of aggressive autoimmune diseases, including multiple sclerosis and scleroderma." To perform a hematopoietic stem cell transplant in a patient of great need, clinicians currently use chemotherapy and radiation to eliminate the patient's own stem cells before introducing the donor's cells. This type of conditioning regimen works by destroying DNA, inflicting a great deal of what Scadden has called "collateral damage," so it comes with serious short- and long-term side effects. Because of those risks, clinicians typically reserve the treatment for only the most desperate patients with cancers and advanced-stage diseases. However, in a recent (June 2016) publication in Nature Biotechnology, members of Scadden's lab led by Harvard/MGH postdoctoral fellow Rahul Palchaudhuri, PhD, along with Boston Children's collaborators Derrick Rossi, PhD, Investigator in the Program in Cellular and Molecular Medicine, and Agnieszka Czechowicz, MD, PhD, Pediatric Hematology/Oncology/Bone Marrow Transplant Fellow, achieved a significant breakthrough. The research team demonstrated a nontoxic transplantation procedure in mice that uses antibodies, instead of chemotherapy and radiation, to specifically target only the blood stem cells. They showed that it successfully removed more than 98 percent of the targeted cells without inflicting the typical side effects. Studies to understand the biological principles had been enabled by grants from the National Institutes of Health (NIH). Harvard's Blavatnik Biomedical Accelerator then provided the lab with financial support and resources to achieve the proof of concept. "That was fantastic," said Scadden, "because it enabled us to do the necessary studies to demonstrate this as a feasible approach and get the sufficient depth of information that it could both be published and be recognized as a path forward for application to patients." Meanwhile, Scadden's lab also made important advances in the way donor cells are selected, harvested, and prepared for transplant. "For people to donate stem cells there are two major options," he explained. "You can go to the operating room and have general anesthesia and have a needle put into the pelvis tens of times, and that's difficult. The other option is to take a medicine for about a week and go to the blood bank and have the stem cells withdrawn from your blood." Instead, members of Scadden's lab led by Harvard/MGH postdoctoral researcher Jonathan Hoggatt, PhD, have developed methods to very rapidly mobilize cells from the bone marrow to the blood so that they could be harvested that same day. "The donor could go to the blood bank, get the medicine injected, be hooked up to the machines, get the blood stem cells withdrawn, and off they go," Scadden predicted. The quality of cell appears to be higher, too, he said: "When we do this strategy of mobilization, we are acquiring what we think is an over-achiever stem cell--what we call a highly engraftable stem cell." Initially funded in part by the NIH and by a corporate partner, aspects of that work were then developed further with a grant from the Massachusetts Life Sciences Center. "A lot of credit goes to the taxpayers of Massachusetts and the leaders of the state that put that all together," Scadden said. "Between the Harvard community and its breadth of connection to both inspired philanthropists like Len Blavatnik and interested biopharma partners and then our own state, it was a great set of partnerships. Their support, from early on, brought our work to the point where it could be attractive to the venture capital founders who are now going to give us the opportunity to really test it and see if we can make a difference for people." In developing the licensed technologies toward new therapeutic strategies, Magenta plans to initially focus on hematologic cancers, hemoglobinopathies, rare genetic diseases, bone marrow failure, and autoimmune diseases. "There has been terrific innovation in stem cell science recently, and it is time to bring this forward to patients," said Magenta CEO Gardner. Scadden plans to serve in a part-time capacity as Magenta's chief scientific advisor and chair of its scientific advisory board. "We're all hopeful that it will result in some people having a better life because of it," Scadden said. "In the meantime it's hopefully employing people, it's driving the science forward, it's creating new businesses in Massachusetts, and I just think all of that is reflective of the fantastic ecosystem here that Harvard plays such an important role in." In addition to Scadden, Palchaudhuri, Hoggatt, Rossi, and Czechowicz, coinventors of the licensed technologies include Borja Saez, PhD (Harvard/MGH), now an Assistant Professor at the University of Pamplona, Spain; and Francesca Ferraro, PhD (Harvard/MGH). Palchaudhuri has now joined Magenta, and Hoggatt is now an assistant professor at MGH and Harvard Medical School. "I'm particularly pleased for the people who were really in the trenches doing the work, who were the source of all the good ideas and doing all the heavy lifting to get it done," Scadden said. "I think it's really tremendously rewarding for them as well. It's the greatest thing possible to have it move to this level." Harvard's Office of Technology Development (OTD) promotes the public good by fostering innovation and translating new inventions made at Harvard University into useful products that are available and beneficial to society. Our integrated approach to technology development comprises sponsored research and corporate alliances, intellectual property management, and technology commercialization through venture creation and licensing. Harvard OTD also manages the Blavatnik Biomedical Accelerator and the Physical Sciences & Engineering Accelerator. For more information, please visit http://otd. . A leader in the field since 2005, the Harvard Stem Cell Institute is focused on bringing stem cell-derived and based treatments to patients as quickly as possible. To accomplish this, we bring together more than 1,000 scientists in the schools and affiliated hospitals of Harvard, fund novel research, and implement new collaborative academic and industrial models.
Arana M.,University of Pamplona
Journal of the Acoustical Society of America | Year: 2010
The majority of acoustic impact studies developed over the last 50 years have used a similar acoustic parameter (Leq, Ldn) but the noise mapping methodology has been very uneven. The selection of the measurement points, the measurement periods, or the evaluation indices have not followed a unique criterion. Therefore, it is not possible to compare the sound pollution levels between different cities from those studies, at least in a rigorous sense. Even more, different studies carried out in the same city by different researchers during different years and using different methodologies are not conclusive whether the acoustic pollution increases or decreases. The present paper shows results, with statistical significance, about the evolution of the acoustic pollution obtained for two Spanish cities, Pamplona and Madrid. In both cases, it can be concluded that noise pollution decreases over time (P<0.01). © 2010 Acoustical Society of America.
Bueno Alastuey M.C.,University of Pamplona
Computer Assisted Language Learning | Year: 2011
This study explored the benefits and drawbacks of synchronous voice-based computer-mediated communication (CMC) in a blended course of English for specific purposes. Quantitative and qualitative data from two groups following the same syllabus, except for the oral component, were compared. Oral tasks were carried out face-to-face with same L1 partners in the control group and through synchronous voice-based CMC with different L1 partners in the experimental group. The analysis included data from general proficiency pre- and post-test scores, oral Power Point presentation grades, students' questionnaires and students' and teachers' diaries. The results showed that achievements were significantly better in the experimental group and that there was also an increase of other positive factors which may effectively contribute both to second language acquisition (SLA) and to solving many of the problems which make speaking skills the weakest skill in foreign language contexts. © 2011 Copyright Taylor and Francis Group, LLC.
Herranz G.,University of Pamplona
Zygote | Year: 2014
In the dominant model, monozygotic (MZ) twinning is universally accepted as a post-fertilization event resulting from splitting of the embryo along its first 2 weeks of development. The stage at which splitting occurs determines chorionicity and amnionicity. A short history on how the model was built is presented, stressing the role played by some embryologists, in particular George Corner, in its completion and final success. Strikingly, for more than 60 years no deep criticisms have been raised against the model, which, in virtue of its rational and plausible character, enjoys the status of undisputed truth. At close examination, the embryological support of the model shows some important weak points, particularly when dealing with late splitting. In the author's view, the model not only has contributed to 'suspend' our knowledge on the timing of MZ twinning, but seems indefensible and claims to be substituted. That factor could imply relevant consequences for embryology and bioethics. As an alternative to the model, a new theory to explain the timing of MZ twinning is proposed. It is based on two premises. First, MZ twinning would be a fertilization event. In that case, due to an alteration of the zygote-blastomere transition, the first zygotic division, instead of producing two blastomeres, generates twin zygotes. Second, monochorionicity and monoamnionicity would not depend on embryo splitting, but on fusion of membranes. Some support for this theory can be found in recent embryological advances and also in some explanations of old. © 2013 Cambridge University Press.
De-Maeztu L.,University of Pamplona |
Villanueva A.,University of Pamplona |
Cabeza R.,University of Pamplona
IEEE Transactions on Pattern Analysis and Machine Intelligence | Year: 2012
Adaptive-weight algorithms currently represent the state of the art in local stereo matching. However, due to their computational requirements, these types of solutions are not suitable for real-time implementation. Here, we present a novel aggregation method inspired by the anisotropic diffusion technique used in image filtering. The proposed aggregation algorithm produces results similar to adaptive-weight solutions while reducing the computational requirements. Moreover, near real-time performance is demonstrated with a GPU implementation of the algorithm. © 2012 IEEE.
Martinez A.,University of Pamplona |
Astrain D.,University of Pamplona |
Rodriguez A.,University of Pamplona
Energy | Year: 2013
Thermoelectric self-cooling systems hold good prospects for the future, since they improve the cooling of any heat-generating device without electricity consumption. The potential number of applications seems to be enormous, hence the necessity of a specific model to simulate this type of thermoelectric application. This paper presents a computational model for thermoelectric self-cooling applications, capable of simulating both the steady and the transient state of the whole system. Supported by fluid-dynamics software and based on the implicit finite differences, the model solves the system of equations composed of the Fourier's law and the thermoelectric effects Seebeck, Peltier, Joule and Thomson, including temperature-dependant properties. Furthermore, the model architecture allows the inclusion of new analytical expressions and/or procedures in order to simulate any component with higher accuracy or include more complex ones. Statistical studies indicate ±12% of maximum deviation between experimental and simulated values of the main outputs. Furthermore, the model simulates the performance of the system under abruptly changing conditions. In conclusion, the computational model turns out to be a powerful tool that will play a key role in the design and development of thermoelectric self-cooling applications. © 2013 Elsevier Ltd.
Restrepo G.,University of Pamplona
Foundations of Chemistry | Year: 2013
By analysing a contemporary criticism to the so called "mathematical chemistry", we discuss what we understand by mathematizing chemistry and its implications. We then pass to ponder on some positions on the subject by considering the cases of Laszlo, Venel and Diderot, opponents to the idea of mathematization of chemistry. In contrast, we analyse some scholars' ideas on the fruitful relationship between mathematics and chemistry; here Dirac and Brown are considered. Finally, we mention that the mathematical-chemistry relationship should be considered beyond the mere aspect of whether chemistry is or not able to be mathematized. This discussion is based upon opinions by Kant and Comte, the first one having two positions on chemistry based upon mathematics and the latter mooting the idea of doing chemistry with mathematical spirit. © 2013 Springer Science+Business Media Dordrecht.